drugset / Trial / NCT00279175

REPAIR-AMI: Intracoronary Progenitor Cells in Acute Myocardial Infarction (AMI)

NCT00279175 ↗

RandomizedParallel-groupQuadruple-blindTreatment

Summary

Impaired contractile function after a heart attack of the heart is a major cause of "heart failure" limiting quality of life and prognosis, which cannot be prevented even with optimal standard therapy, including immediate balloon/stent dilation of the infarct vessel. The aim of the REPAIR-AMI trial is to investigate whether infusion of progenitor cells into the infarct vessel (after successful reperfusion therapy) may improve left ventricular contractile function compared to placebo therapy. After bone marrow aspiration progenitor cells are enriched via a centrifugation method.

Timeline

Start
2004-04
Primary completion
2005-10
Completion
2010-12

Outcome

Met primary endpoint

paper the absolute improvement in the global left ventricular ejection fraction (LVEF) was significantly greater in the BMC group than in the placebo group PMID 16990384 ↗

paper mean [+/-SD] increase, 5.5+/-7.3% vs. 3.0+/-6.5%; P=0.01 PMID 16990384 ↗

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject bone marrow-derived progenitor cells Cell therapy — Other

Indications